<DOC>
	<DOCNO>NCT01669902</DOCNO>
	<brief_summary>This multicenter observational study evaluate use RoActemra/Actemra ( tocilizumab ) monotherapy patient active moderate severe rheumatoid arthritis unable use methotrexate . Eligible patient initiated RoActemra/Actemra treatment follow 6 month .</brief_summary>
	<brief_title>An Observational Study RoActemra/Actemra ( Tocilizumab ) Monotherapy Patients With Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<criteria>Adult patient , &gt; /= 18 year age Moderate severe rheumatoid arthritis accord revise ( 1987 ) ACR criterion Patients reason take methotrexate treat physician make decision prescribe RoActemra/Actemra monotherapy ; patient commence RoActemra/Actemra monotherapy within 8 week prior enrolment visit may include Concomitant treatment nonsteroidal antiinflammatory drug ( NSAID ) corticosteroid ( orally intraarticularly ) allow Patients receive RoActemra/Actemra 8 week prior enrolment visit Previous RoActemra/Actemra treatment clinical trial compassionate use Concomitant DMARD treatment rheumatoid arthritis ( e.g . hyroxychloroquine , sulfasalazine , methotrexate , leflunomide , gold compound , cyclosporine ) Treatment investigational agent within 4 week ( 5 halflives investigational agent , whichever long ) start RoActemra/Actemra treatment History autoimmune disease joint inflammatory disease rheumatoid arthritis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>